A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/09 (2006.01) A61K 39/385 (2006.01) A61K 39/39 (2006.01) A61K 47/48 (2006.01) A61P 31/04 (2006.01)
Patent
CA 2364442
The invention relates to a method for preventing against diseases induced by Streptococcus pneumoniae infections, which comprises mucosally administering to a patient in need of a S. pneumoniae capsular polysaccharide. This latter may be conjugated or not and is preferably mixed with a mucosal adjuvant such as cholera toxin, E. coli heatlabile toxin or RhinovaxTM. A preferred route of administration is the intranasal route.
L'invention concerne une méthode de prévention contre des maladies induites par des infections à streptococcus pneumoniae, laquelle consiste en une administration par la muqueuse à un patient nécessitant un polysaccharide capsulaire de S. pneumoniae. Ce dernier peut être conjugué ou non et il est de préférence mélangé à un adjuvant muqueux tel qu'une toxine de choléra, une toxine thermolabile de E. coli ou du Rhinovax?MC¿. Une voie d'administration préférée est la voie intranasale.
Aventis Pasteur
Jonsdottir Ingileif
Robic
LandOfFree
Intranasal delivery of pneumococcal polysaccharide vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Intranasal delivery of pneumococcal polysaccharide vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Intranasal delivery of pneumococcal polysaccharide vaccines will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2083192